Zuckerman Tsila, Rowe Jacob M
Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, 8 Haalia Hshnia Street, Bat Galim, Haifa 3525408, Israel; The Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Efron Street, P.O.B. 9649, Bat Galim, Haifa 31096, Israel.
Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, 8 Haalia Hshnia Street, Bat Galim, Haifa 3525408, Israel; The Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Efron Street, P.O.B. 9649, Bat Galim, Haifa 31096, Israel; Department of Hematology, Shaare Zedek Medical Center, 12 Shmuel Bait Street, Jerusalem 9102102, Israel.
Hematol Oncol Clin North Am. 2014 Dec;28(6):983-94. doi: 10.1016/j.hoc.2014.08.016. Epub 2014 Sep 30.
Acute myeloid leukemia (AML) is associated with poor outcome mainly because of relapse. The best antileukemic treatment is allogeneic stem cell transplantation. However, the associated significant nonrelapse mortality limits both the application and outcome of the procedure. Recent advances in understanding the genetic landscape of the disease enable educated selection of patients. Improved treatment protocols, supportive therapy, patient selection, and posttransplant manipulations all contribute to a better outcome.
